Does the media favor CYTK or TRVI?

In the previous week, Trevi Therapeutics had 1 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Trevi Therapeutics and 11 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.95 beat Trevi Therapeutics' score of 0.89 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, TRVI or NUVL?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is TRVI or NUVL more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Nuvalent N/A -40.11% -35.43%

Does the media favor TRVI or NUVL?

In the previous week, Trevi Therapeutics had 4 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Trevi Therapeutics and 8 mentions for Nuvalent. Trevi Therapeutics' average media sentiment score of 0.89 beat Nuvalent's score of 0.03 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor KYMR or TRVI?

In the previous week, Trevi Therapeutics had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Trevi Therapeutics and 8 mentions for Kymera Therapeutics. Trevi Therapeutics' average media sentiment score of 0.89 beat Kymera Therapeutics' score of 0.47 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trevi Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRVI or IBRX?

In the previous week, Trevi Therapeutics had 2 more articles in the media than ImmunityBio. MarketBeat recorded 12 mentions for Trevi Therapeutics and 10 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.06 beat Trevi Therapeutics' score of 0.89 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is TRVI or PRAX more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Praxis Precision Medicines N/A -43.02% -40.22%

Does the media refer more to TRVI or PRAX?

In the previous week, Trevi Therapeutics had 8 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Trevi Therapeutics and 4 mentions for Praxis Precision Medicines. Trevi Therapeutics' average media sentiment score of 0.89 beat Praxis Precision Medicines' score of 0.50 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Trevi Therapeutics (TRVI) Competitors

$16.77 -2.30 (-12.06%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$17.02 +0.25 (+1.52%)

As of 08:09 AM Eastern

Compare

TRVI vs. CYTK, NUVL, KYMR, IBRX, and PRAX

Should you buy Trevi Therapeutics stock or one of its competitors? MarketBeat compares Trevi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevi Therapeutics include Cytokinetics (CYTK), Nuvalent (NUVL), Kymera Therapeutics (KYMR), ImmunityBio (IBRX), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Trevi Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Trevi Therapeutics has lower revenue, but higher earnings than Cytokinetics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	111.81	-$784.96M	-$6.84	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

95.8% of Trevi Therapeutics shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Trevi Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Cytokinetics currently has a consensus price target of $99.90, suggesting a potential upside of 26.28%. Trevi Therapeutics has a consensus price target of $24.91, suggesting a potential upside of 48.53%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

In the previous week, Trevi Therapeutics had 1 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Trevi Therapeutics and 11 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.95 beat Trevi Therapeutics' score of 0.89 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Trevi Therapeutics beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Nuvalent?

Trevi Therapeutics (NASDAQ:TRVI) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Trevi Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Nuvalent has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

In the previous week, Trevi Therapeutics had 4 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Trevi Therapeutics and 8 mentions for Nuvalent. Trevi Therapeutics' average media sentiment score of 0.89 beat Nuvalent's score of 0.03 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by insiders. Comparatively, 5.0% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Trevi Therapeutics' return on equity of -24.53% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Nuvalent	N/A	-40.11%	-35.43%

Trevi Therapeutics presently has a consensus target price of $24.91, indicating a potential upside of 48.53%. Nuvalent has a consensus target price of $127.73, indicating a potential upside of 3.04%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Trevi Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Summary

Trevi Therapeutics beats Nuvalent on 11 of the 14 factors compared between the two stocks.

How does Trevi Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Trevi Therapeutics had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 12 mentions for Trevi Therapeutics and 8 mentions for Kymera Therapeutics. Trevi Therapeutics' average media sentiment score of 0.89 beat Kymera Therapeutics' score of 0.47 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics currently has a consensus target price of $122.64, indicating a potential upside of 10.42%. Trevi Therapeutics has a consensus target price of $24.91, indicating a potential upside of 48.53%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Kymera Therapeutics has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

95.8% of Trevi Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 15.4% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Trevi Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Trevi Therapeutics' return on equity of -24.53% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Trevi Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	233.00	-$311.35M	-$3.57	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

Summary

Trevi Therapeutics beats Kymera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to ImmunityBio?

Trevi Therapeutics (NASDAQ:TRVI) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Trevi Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
ImmunityBio	-606.15%	N/A	-59.53%

Trevi Therapeutics has higher earnings, but lower revenue than ImmunityBio. Trevi Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
ImmunityBio	$113.29M	69.24	-$351.40M	-$0.85	N/A

Trevi Therapeutics has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, ImmunityBio has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Trevi Therapeutics presently has a consensus target price of $24.91, suggesting a potential upside of 48.53%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 89.59%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Trevi Therapeutics had 2 more articles in the media than ImmunityBio. MarketBeat recorded 12 mentions for Trevi Therapeutics and 10 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.06 beat Trevi Therapeutics' score of 0.89 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Trevi Therapeutics beats ImmunityBio on 10 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Trevi Therapeutics (NASDAQ:TRVI) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Trevi Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Praxis Precision Medicines has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market.

Trevi Therapeutics presently has a consensus target price of $24.91, suggesting a potential upside of 48.53%. Praxis Precision Medicines has a consensus target price of $563.50, suggesting a potential upside of 85.10%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95

Trevi Therapeutics' return on equity of -24.53% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Trevi Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Praxis Precision Medicines	$8.55M	992.69	-$303.27M	-$13.37	N/A

In the previous week, Trevi Therapeutics had 8 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Trevi Therapeutics and 4 mentions for Praxis Precision Medicines. Trevi Therapeutics' average media sentiment score of 0.89 beat Praxis Precision Medicines' score of 0.50 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Trevi Therapeutics beats Praxis Precision Medicines on 8 of the 15 factors compared between the two stocks.

Get Trevi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVI vs. The Competition

Export

Metric	Trevi Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.71B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-52.41	20.49	27.07	23.95
Price / Sales	N/A	300.33	515.05	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	11.73	7.92	10.62	6.14
Net Income	-$42.76M	$23.81M	$3.60B	$331.74M
7 Day Performance	-6.37%	-1.09%	-1.26%	-1.82%
1 Month Performance	-2.56%	2.56%	1.07%	-1.45%
1 Year Performance	145.89%	42.16%	23.63%	16.32%

Trevi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVI Trevi Therapeutics	3.4972 of 5 stars	$16.77 -12.1%	$24.91 +48.5%	+144.5%	$2.71B	N/A	N/A	20	News Coverage Positive News Analyst Forecast
CYTK Cytokinetics	3.2472 of 5 stars	$82.54 -3.5%	$99.90 +21.0%	+112.5%	$10.25B	$88.04M	N/A	250
NUVL Nuvalent	2.2002 of 5 stars	$123.81 +0.0%	$127.73 +3.2%	N/A	$9.78B	N/A	N/A	40	Analyst Upgrade
KYMR Kymera Therapeutics	1.7004 of 5 stars	$115.04 -3.5%	$121.41 +5.5%	+140.5%	$9.47B	$39.21M	N/A	170
IBRX ImmunityBio	3.5276 of 5 stars	$8.64 -1.4%	$14.20 +64.4%	+172.4%	$9.04B	$113.29M	N/A	590	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVI) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevi Therapeutics (TRVI) Competitors

TRVI vs. CYTK, NUVL, KYMR, IBRX, and PRAX

How does Trevi Therapeutics compare to Cytokinetics?

Summary

How does Trevi Therapeutics compare to Nuvalent?

Summary

How does Trevi Therapeutics compare to Kymera Therapeutics?

Summary

How does Trevi Therapeutics compare to ImmunityBio?

Summary

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevi Therapeutics (TRVI) Competitors

TRVI vs. CYTK, NUVL, KYMR, IBRX, and PRAX

How does Trevi Therapeutics compare to Cytokinetics?

Which has preferable valuation and earnings, CYTK or TRVI?

Do institutionals & insiders hold more shares of CYTK or TRVI?

Is CYTK or TRVI more profitable?

Do analysts recommend CYTK or TRVI?

Which has more risk and volatility, CYTK or TRVI?

Does the media favor CYTK or TRVI?

Summary

How does Trevi Therapeutics compare to Nuvalent?

Which has preferable valuation & earnings, TRVI or NUVL?

Which has more volatility & risk, TRVI or NUVL?

Does the media favor TRVI or NUVL?

Do institutionals & insiders hold more shares of TRVI or NUVL?

Is TRVI or NUVL more profitable?

Do analysts rate TRVI or NUVL?

Summary

How does Trevi Therapeutics compare to Kymera Therapeutics?

Does the media favor KYMR or TRVI?

Do analysts rate KYMR or TRVI?

Which has more volatility and risk, KYMR or TRVI?

Do insiders and institutionals believe in KYMR or TRVI?

Is KYMR or TRVI more profitable?

Which has higher valuation and earnings, KYMR or TRVI?

Summary

How does Trevi Therapeutics compare to ImmunityBio?

Do insiders and institutionals hold more shares of TRVI or IBRX?

Is TRVI or IBRX more profitable?

Which has higher earnings & valuation, TRVI or IBRX?

Which has more risk & volatility, TRVI or IBRX?

Do analysts rate TRVI or IBRX?

Does the media favor TRVI or IBRX?

Summary

How does Trevi Therapeutics compare to Praxis Precision Medicines?

Which has more risk & volatility, TRVI or PRAX?

Do analysts rate TRVI or PRAX?

Is TRVI or PRAX more profitable?

Do insiders and institutionals hold more shares of TRVI or PRAX?

Which has better earnings & valuation, TRVI or PRAX?

Does the media refer more to TRVI or PRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools